ECSP24032316A - Derivados de amina bicíclicos como moduladores de receptor gabaa alfa 5 - Google Patents
Derivados de amina bicíclicos como moduladores de receptor gabaa alfa 5Info
- Publication number
- ECSP24032316A ECSP24032316A ECSENADI202432316A ECDI202432316A ECSP24032316A EC SP24032316 A ECSP24032316 A EC SP24032316A EC SENADI202432316 A ECSENADI202432316 A EC SENADI202432316A EC DI202432316 A ECDI202432316 A EC DI202432316A EC SP24032316 A ECSP24032316 A EC SP24032316A
- Authority
- EC
- Ecuador
- Prior art keywords
- gabaa
- receptor
- alfa
- receptor modulators
- amine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención proporciona compuestos de la fórmula (I) y/o sales de este y/o estereoisómeros de estos y/o enantiómeros de estos y/o racematos de estos y/o diastereómeros de estos y/o metabolitos biológicamente activos de estos y/o profármacos de estos y/o solvatos de estos y/o hidratos de estos y/o polimorfos de estos que tienen afinidad y selectividad por el receptor A subunidad α5 del ácido γ-aminobutírico y actúan como moduladores alostéricos positivos del receptor GABAA α5, lo que les permite ser útiles en el tratamiento o la prevención de enfermedades relacionadas con el receptor GABAA α5, en el proceso para la preparación de estos y en los productos intermedios de la preparación de estos, en las composiciones farmacéuticas que los comprenden solos o en combinación con uno o más principios activos diferentes y en su uso como medicamentos. (I)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP2100338A HU231691B1 (hu) | 2021-09-29 | 2021-09-29 | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
| PCT/IB2022/059214 WO2023053015A1 (en) | 2021-09-29 | 2022-09-28 | BICYCLIC AMINE DERIVATIVES AS GABAA α5 RECEPTOR MODULATORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP24032316A true ECSP24032316A (es) | 2024-05-31 |
Family
ID=89993434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202432316A ECSP24032316A (es) | 2021-09-29 | 2024-04-26 | Derivados de amina bicíclicos como moduladores de receptor gabaa alfa 5 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20250051323A1 (es) |
| EP (1) | EP4408842A1 (es) |
| JP (1) | JP2024536039A (es) |
| KR (1) | KR20240089056A (es) |
| CN (1) | CN118284606A (es) |
| AR (1) | AR127182A1 (es) |
| AU (1) | AU2022357572A1 (es) |
| CA (1) | CA3231776A1 (es) |
| CL (1) | CL2024000893A1 (es) |
| CO (1) | CO2024005424A2 (es) |
| CU (1) | CU20240013A7 (es) |
| EC (1) | ECSP24032316A (es) |
| GE (2) | GEP20257812B (es) |
| HU (1) | HU231691B1 (es) |
| IL (1) | IL311640A (es) |
| JO (1) | JOP20240057A1 (es) |
| MX (1) | MX2024003812A (es) |
| PE (1) | PE20240816A1 (es) |
| TW (1) | TW202330518A (es) |
| WO (1) | WO2023053015A1 (es) |
| ZA (1) | ZA202403230B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119080754A (zh) * | 2023-06-05 | 2024-12-06 | 武汉人福创新药物研发中心有限公司 | 作为α5-GABAA受体调节剂的杂环化合物及其用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU230518B1 (hu) | 2005-12-20 | 2016-10-28 | Richter Gedeon Nyrt. | Bradykinin B1 receptor szelektív antagonista hatással rendelkező új fenatridin származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények |
| HUP0600809A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| HUP0600810A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| HUP0600808A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New benzamide derivatives as bradykinin antagonists, process for their preparation and pharmaceutical compositions containing them |
| US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| US8742097B2 (en) | 2010-11-09 | 2014-06-03 | Hoffmann-La Roche Inc. | Triazole compounds I |
| US9475797B2 (en) | 2012-06-26 | 2016-10-25 | Saniona A/S | Phenyl triazole derivative and its use for modulating the GABAA receptor complex |
| WO2014001278A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| WO2014001279A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| HUP1300139A2 (en) | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
| NZ760341A (en) | 2013-12-20 | 2021-12-24 | Agenebio Inc | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| HRP20221098T1 (hr) | 2016-03-18 | 2022-11-25 | Uwm Research Foundation, Inc. | Tretman kognitivnih i simptoma poremećaja raspoloženja kod neurodegenerativnih i neuropsihijatrijskih poremećaja agonistima gabaa receptora koji sadrže alfa5 |
| ES2910110T3 (es) | 2016-12-08 | 2022-05-11 | Hoffmann La Roche | Nuevos derivados de isoxazolil-éter como PAM de alfa 5 GABA A |
| HU231058B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt. | Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| HU231057B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt | Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| TW201938171A (zh) | 2017-12-15 | 2019-10-01 | 匈牙利商羅特格登公司 | 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物 |
| HU231206B1 (hu) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
| IL279266B2 (en) | 2018-06-13 | 2024-03-01 | Hoffmann La Roche | New isoxazolyl ether derivatives as gaba a alpha5 pam |
| HU231478B1 (hu) | 2018-07-13 | 2024-02-28 | Richter Gedeon Nyrt. | Szubsztituált (aza)indol származékok |
| HU231333B1 (hu) | 2018-07-13 | 2023-01-28 | Richter Gedeon Nyrt | Spirokromán származékok |
| HU231414B1 (hu) | 2018-07-13 | 2023-08-28 | Richter Gedeon Nyrt. | Tiadiazin származékok |
| BR102019014802A2 (pt) | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
| HU231223B1 (hu) * | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | GABAA A5 receptor modulátor hatású biciklusos vegyületek |
| TWI901650B (zh) * | 2020-03-26 | 2025-10-21 | 匈牙利商羅特格登公司 | 啶及吡啶并〔３，４－ｃ〕嗒衍生物 |
-
2021
- 2021-09-29 HU HUP2100338A patent/HU231691B1/hu unknown
-
2022
- 2022-09-13 TW TW111134580A patent/TW202330518A/zh unknown
- 2022-09-28 JP JP2024518133A patent/JP2024536039A/ja active Pending
- 2022-09-28 CN CN202280074314.9A patent/CN118284606A/zh active Pending
- 2022-09-28 GE GEAP202216510A patent/GEP20257812B/en unknown
- 2022-09-28 WO PCT/IB2022/059214 patent/WO2023053015A1/en not_active Ceased
- 2022-09-28 PE PE2024000597A patent/PE20240816A1/es unknown
- 2022-09-28 IL IL311640A patent/IL311640A/en unknown
- 2022-09-28 CU CU2024000013A patent/CU20240013A7/es unknown
- 2022-09-28 MX MX2024003812A patent/MX2024003812A/es unknown
- 2022-09-28 EP EP22783047.8A patent/EP4408842A1/en active Pending
- 2022-09-28 CA CA3231776A patent/CA3231776A1/en active Pending
- 2022-09-28 AU AU2022357572A patent/AU2022357572A1/en active Pending
- 2022-09-28 KR KR1020247013656A patent/KR20240089056A/ko active Pending
- 2022-09-28 GE GEAP202416510A patent/GEAP202416510A/en unknown
- 2022-09-28 US US18/696,506 patent/US20250051323A1/en active Pending
- 2022-09-29 AR ARP220102623A patent/AR127182A1/es unknown
-
2024
- 2024-03-20 JO JOJO/P/2024/0057A patent/JOP20240057A1/ar unknown
- 2024-03-27 CL CL2024000893A patent/CL2024000893A1/es unknown
- 2024-04-25 ZA ZA2024/03230A patent/ZA202403230B/en unknown
- 2024-04-26 EC ECSENADI202432316A patent/ECSP24032316A/es unknown
- 2024-04-26 CO CONC2024/0005424A patent/CO2024005424A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024003812A (es) | 2024-04-25 |
| JOP20240057A1 (ar) | 2024-03-20 |
| GEAP202416510A (en) | 2024-08-12 |
| CU20240013A7 (es) | 2024-11-15 |
| WO2023053015A1 (en) | 2023-04-06 |
| HU231691B1 (hu) | 2025-10-28 |
| CL2024000893A1 (es) | 2024-09-06 |
| US20250051323A1 (en) | 2025-02-13 |
| KR20240089056A (ko) | 2024-06-20 |
| TW202330518A (zh) | 2023-08-01 |
| CN118284606A (zh) | 2024-07-02 |
| AU2022357572A1 (en) | 2024-05-02 |
| PE20240816A1 (es) | 2024-04-18 |
| JP2024536039A (ja) | 2024-10-04 |
| EP4408842A1 (en) | 2024-08-07 |
| ZA202403230B (en) | 2024-12-18 |
| HUP2100338A1 (hu) | 2023-04-28 |
| GEP20257812B (en) | 2025-10-27 |
| IL311640A (en) | 2024-05-01 |
| CO2024005424A2 (es) | 2024-05-10 |
| CA3231776A1 (en) | 2023-04-06 |
| AR127182A1 (es) | 2023-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21080740A (es) | Inhibidores del inflamasoma nlrp3 | |
| CL2021000191A1 (es) | Inhibidores de inflamasoma nlrp3 | |
| CO2022015054A2 (es) | [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2 | |
| CL2021000907A1 (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 (divisional de solicitud n° 01501-2020) | |
| DOP2021000198A (es) | Compuestos y su uso en el tratamiento del cáncer | |
| CO6251367A2 (es) | Derivados de 6-amino-5-aril piridina-2il-carboxamida | |
| UY29827A1 (es) | 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones | |
| AR123685A1 (es) | Antagonistas del mrgx2 | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| DOP2025000013A (es) | Inhibidores de inflamasoma nlrp3 | |
| CL2020001564A1 (es) | Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresina. | |
| ECSP19072975A (es) | Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos | |
| ECSP24032316A (es) | Derivados de amina bicíclicos como moduladores de receptor gabaa alfa 5 | |
| MX2020007443A (es) | Derivados de 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona y compuestos relacionados como moduladores del receptor c5a para el tratamiento de vasculitis y enfermedades inflamatorias. | |
| CL2025000120A1 (es) | Compuestos de piridinona sustituida como inhibidores de cbl-b. | |
| EA202190857A1 (ru) | Бициклические производные как модуляторы 5 рецепторов gabaa | |
| MX2022011354A (es) | Compuestos de pirimidina fusionados como moduladores de kcc2. | |
| CO2022014877A2 (es) | Derivados de naftiridina y pirido[3,4-c]piridazina como moduladores del receptor gabaa α5 | |
| UY37745A (es) | Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias | |
| UY38550A (es) | Compuestos inhibidores de inflamasoma nlrp3, composiciones, combinaciones y métodos relacionados | |
| AR134411A1 (es) | Compuestos de uracilo | |
| DOP2007000086A (es) | Nuevos derivados de quinolinas |